Metal-Based Drugs

Metal-Based Drugs / 2009 / Article / Tab 2

Research Article

Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion

Table 2

Effect of KP1019 on lung metastases formation in mice with MCa mammary carcinoma.

(A)Primary tumour weight (mg)Lung metastases
Day 13Day 20NumberWeight (mg)

Controls1627 2863068 61629.2 8.1018.6 12.1
KP1019 40 mg1095 5922537 56331.9 19.211.8 11.8
(67%)(83%)(109%)(63%)

(B)Primary tumour weight (mg)Lung Metastases
Day 13Day 20NumberWeight (mg)

Controls1004 1742415 43917.5 10.05.70 6.90
KP1019 80 mg527 136.66 1764 37 19.9 23.2#3.43 5.83#
(52%)(73%)(114%)(60%)

Groups of 9 (experiment A) or 11 (experiment B) CBA mice, inoculated I.M. with  MCa tumour cells on day 0 were treated I.P. with KP1019 at 40 mg/kg/day from day 6 to day 11 (A) and 80 mg/kg/day on days 7, 9, and 11 (B) after tumour implant. Data in parentheses are expressed as the percentage of the treated versus controls (T/C%), Lung metastases were determined on day 20 after tumour implant, : versus controls, ANOVA, and Tukey-Kramer post test, #: excluded the animals free of macroscopically detectable metastasis (2/11).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.